4.7 Review

The biology of PGC-1α and its therapeutic potential

期刊

TRENDS IN PHARMACOLOGICAL SCIENCES
卷 30, 期 6, 页码 322-329

出版社

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2009.03.006

关键词

-

资金

  1. Swiss National Science Foundation [SNF PP00A110746]
  2. Muscular Dystrophy Association USA
  3. SwissLife 'Jubilaumsstiftung fur Volksgesundheit und medizinische Forschung'
  4. Swiss Society for Research on Muscle Diseases
  5. Swiss Diabetes Association
  6. Roche Research Foundation
  7. Zurich Center for Integrative Human Physiology
  8. Universities of Basel and Zurich

向作者/读者索取更多资源

In eukaryotes, cellular and. systemic metabolism is primarily controlled by mitochondrial activity. The peroxisome proliferator-activated receptor gamma coactivator let (PGC-1 alpha) is an important regulator of mitochondrial biogenesis and function. Furthermore, PGC-1 alpha controls many of the phenotypic adaptations of oxidative tissues to external and internal perturbations. By contrast, dysregulated metabolic plasticity is involved in the etiology of numerous diseases. Accordingly, modulation of PGC-1 alpha levels and activity has recently been proposed as a therapeutic option for several pathologies. However, pharmacological interventions aimed at PGC-1 alpha have to overcome inherent limitations of targeting a coactivator protein. Here, I focus on the recent breakthroughs in the identification of physiological and pathophysiological contexts involving PGC-1 alpha. In addition, perspectives regarding the therapeutic importance of PGC-1 alpha-controlled cellular and systemic metabolism are outlined.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据